Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has significantly reduced the efficacy of some approved vaccines. A fourth dose of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant spike [rS] protein + 50 µg Matrix-M™ adjuvant; Novavax, Gaithersburg, MD) was evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Katia, Plested, Joyce S., Galbiati, Shirley, Chau, Gordon, Cloney-Clark, Shane, Zhu, Mingzhu, Kalkeri, Raj, Patel, Nita, Smith, Kathy, Marcheschi, Alex, Pfeiffer, Susan, McFall, Heather, Smith, Gale, Glenn, Gregory M., Dubovsky, Filip, Mallory, Raburn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237325/
https://www.ncbi.nlm.nih.gov/pubmed/37271706
http://dx.doi.org/10.1016/j.vaccine.2023.05.051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10237325/
https://www.ncbi.nlm.nih.gov/pubmed/37271706
http://dx.doi.org/10.1016/j.vaccine.2023.05.051

Ejemplares similares